Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

I. Scher, Howard; Lu, David; A. Schreiber, Nicole; Louw, Jessica; P. Graf, Ryon; Alberto Vargas, Hebert; Johnson, Ann; Jendrisak, Adam; Bambury, Richard; C. Danila, Daniel; McLaughlin, Brigit; Wahl, Justin; Greene, Stephanie; Heller, Glenn; Marrinucci, Dena; Fleisher, Martin; Dittamore, Ryan

doi:10.1001/jamaoncol.2016.1828

Public

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Published in JAMA Oncology • Jun 4, 2016

Authors:

Howard I. Scher

David Lu

Nicole A. Schreiber

Abstract

IMPORTANCE: A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane. OBJECTIVE: To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression a...

Subject

Medicine

Taxane

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!